Exclusive Summary

• Backed by highly scarce US-FDA and PH-FDA certifications, enabling distribution partners to achieve ultra-fast market access in Southeast Asia, MENA, and LATAM via regulatory reliance pathways.
• As the latest-generation premium ARB for first-line hypertension treatment, it offers superior 24-hour blood pressure control over classic ARBs, perfectly addressing the upgraded treatment needs of over 1.28 billion global patients.
• Strategically timed for the looming originator 'patent cliff', offering partners the golden opportunity to capture early-mover generic substitution market share.
• Avoids the highly saturated red ocean of classic ARBs completely, leveraging China's cost-efficient supply chain to provide highly attractive profit margins for local distributors.